• Aerie Announces Drug Application for Approval Accepted for Review in Europe americanpharmaceuticalreview
    October 12, 2018
    Aerie Pharmaceuticals reported the EMA has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated intraocular press
PharmaSources Customer Service